Degenerative joint diseases that ultimately lead to osteoarthritis considerably reduce the quality of life of sufferers.
Degenerative joint diseases that ultimately lead to osteoarthritis considerably reduce the quality of life of sufferers. Fortigel specifically stimulates cartilage cells and enhances the synthesis of cartilage tissue. In this way, Fortigel is a new and powerful agent for counteracting the progressive loss of joint cartilage by actually fighting the cause rather than only targeting the symptoms of the problem. After simple pain-killers and chondroitin/glucosamine, which at best only affect 25% of the cartilage, Fortigel could well be called “The Third Generation of Joint Care.”
This revolutionary effect of Foritgel has been confirmed in numerous international preclinical and clinical studies conducted by independent and renowned research institutes, such as the Collagen Research Institute in Kiel, Germany, and Harvard University and Tufts University, both near Boston.
To demonstrate how easily Fortigel can be formulated in a wide range of products from liquid or solid dietary supplements to enriched foods, Gelita will provide a number of prototypes and application concepts for tasting at the IFT Show in Anaheim, Calif., Booth 2719. Learn more about Fortigel in a special IFT presentation at 1 p.m. June 7 in the Hall A theatre (booth 583).
Gelita USA Inc.